$60M in, Ab­b­Vie is trig­ger­ing a $625M-plus plan to de­vel­op a new im­muno-on­col­o­gy drug that is go­ing af­ter GARP

Ab­b­Vie $AB­BV has de­cid­ed to jump in­to clin­i­cal de­vel­op­ment work with a new im­muno-on­col­o­gy drug for its on­col­o­gy pipeline. 

Two years af­ter the com­pa­ny com­mit­ted $60 mil­lion in an up­front and near-term pre­clin­i­cal mile­stones to its part­ner ar­genx (Eu­ronext Brus­sels: ARGX), re­searchers are com­ing back for the com­mer­cial rights to a ther­a­py dubbed ARGX-115. And Ab­b­Vie — which has fin­ished pay­ing the full $20 mil­lion in ear­ly goal pay­ments — is down for up to $625 mil­lion in mile­stones if it can make the drug work as hoped.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.